Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Choksi AsiaBOM:530427 +2.88%52 3-Year RORE % is 38.04 as of Jun. 2026. GuruFocus rates BOM:530427 with a GF Score™ of 52/100. The stock has 8 warning signs investors should review. Among 780 Medical Devices & Instruments companies, Choksi Asia ranks better than 82.82% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Choksi Asia's 3-Year RORE % for the quarter that ended in Jun. 2026 was 38.04%.
The industry rank for Choksi Asia's 3-Year RORE % or its related term are showing as below:
BOM:530427's 3-Year RORE % is ranked better than 82.82% of 780
companies
in the Medical Devices & Instruments industry
Industry Median: -3.06
vs BOM:530427: 38.04
Choksi Asia (BOM:530427) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Choksi Asia 3-Year RORE % Related Terms
Choksi Asia 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Choksi Asia's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:530427 vs ABT, SYK, MDT: 3-Year RORE % Comparison
For the Medical Devices subindustry, Choksi Asia's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Choksi Asia 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Choksi Asia's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Choksi Asia's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2026 and 3-year before.
Choksi Asia (BOM:530427) has a 3-Year RORE % of 38.04 as of Jun. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Choksi Asia and its competitors. According to the industry distribution chart, Choksi Asia ranks #134 out of 780 companies in the Medical Devices & Instruments industry, placing it in the top 17.2%.
Is Choksi Asia's 3-Year RORE % too high?
Choksi Asia's current 3-Year RORE % is 38.04. Based on the distribution chart, Choksi Asia ranks #134 out of 780 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Choksi Asia has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Choksi Asia's 3-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Choksi Asia ranks #134 out of 780 companies for 3-Year RORE %. This places Choksi Asia in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Choksi Asia and its competitors. Choksi Asia's current 3-Year RORE % is 38.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Choksi Asia stock overvalued right now?
Choksi Asia (BOM:530427) has a current 3-Year RORE % of 38.04. The current 3-Year RORE % is 38.04. Choksi Asia's overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Choksi Asia (BOM:530427), the current 3-Year RORE % is 38.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Choksi Asia Ltd formerly Choksi Imaging Ltd is an India-based company engaged in the manufacturing of photosensitized materials, medical X-rays, and other healthcare products. The company sells and derives revenue from products like X-ray films, ultrasound, computed radiography systems, specialty X-ray films, etc. In addition, the company also offers maintenance services for X-ray processors, equipment, and computer radiography systems. The firm provides various photographic, and ultrasonic sound services in association with Protec, Medtron, and others.
52GF Score
Get the complete analysis for BOM:530427
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530427 has been successfully added to your 
